[ ]
Сарграмостим (Sargramostim)
Международное непатентованное наименование Сарграмостим (Sargramostim)
Торговое наименование Leukine
Производитель, страна Bayer AG, Germany
Лекарственная форма injection, for subcutaneous or intravenous use
Механизм действия

Sargramostim is primarily used for myeloid reconstitution after autologous or allogeneic bone marrow transplantation. It is also used to treat neutropenia induced by chemotherapy during the treatment of acute myeloid leukemia. It also used as a medical countermeasure for treating people who have been exposed to sufficient radiation to suppress bone marrow myelogenesis.

Опыт использования

FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation.

Публикации COVID-19

Giovanni DamianiThomas S McCormick, et al. Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor Expressed in Yeast (Sargramostim): A Potential Ally to Combat Serious Infections. Clin Immunol. 2020 Jan;210:108292. DOI: 10.1016/j.clim.2019.108292.

Клинические исследования
Название протокола A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure
Дата начала и окончания КИ March 24, 2020 - December 31, 2020
Название организации, проводящей КИ University Hospital, Ghent
Страны Belgium
Фаза IV
Кол-во пациентов 80